ERBB2 and breast cancer: Preclinical studies suggest that the activity of certain antibody drug conjugates (ADC) may be dependent on the expression levels of HER2 protein rather than on HER2 amplification [16], and some data seem to show promising results with trastuzumab deruxtecan in advanced HER2-low BC [17], rather than a bystander effect.